DocGo Inc. (NASDAQ:DCGO) Receives Average Rating of "Hold" from Brokerages

Key Points

• DocGo Inc. has received an average rating of "Hold" from seven brokerages, with two sell recommendations, three holds, and two buys.
• The company’s stock price has seen a decline, currently at $1.15, down 4.2%, with a 52-week range between $1.12 and $5.68.
• In its latest earnings report, DocGo missed the EPS consensus estimate, reporting ($0.11) while revenue was $80.42 million, exceeding expectations.

Shares of DocGo Inc. (NASDAQ:DCGO - Get Free Report) have earned an average rating of "Hold" from the seven research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $3.2375.

Several analysts have commented on DCGO shares. Weiss Ratings reissued a "sell (d)" rating on shares of DocGo in a report on Wednesday. Canaccord Genuity Group raised their price objective on DocGo from $1.45 to $1.60 and gave the company a "hold" rating in a report on Thursday, August 21st. Finally, Zacks Research lowered DocGo from a "hold" rating to a "strong sell" rating in a report on Tuesday.

DocGo Stock Down 4.2%

DocGo stock opened at $1.15 on Friday. The firm has a market cap of $112.48 million, a price-to-earnings ratio of -6.05 and a beta of 0.95. DocGo has a 52 week low of $1.12 and a 52 week high of $5.68. The business's 50-day moving average price is $1.49 and its 200 day moving average price is $1.70.

DocGo (NASDAQ:DCGO - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). DocGo had a negative return on equity of 3.26% and a negative net margin of 4.20%.The company had revenue of $80.42 million for the quarter, compared to analyst estimates of $77.58 million. DocGo has set its FY 2025 guidance at EPS. Equities analysts expect that DocGo will post 0.25 EPS for the current year.

Institutional Trading of DocGo

A number of institutional investors have recently made changes to their positions in the company. Brandywine Global Investment Management LLC boosted its stake in shares of DocGo by 12.0% in the first quarter. Brandywine Global Investment Management LLC now owns 77,269 shares of the company's stock worth $204,000 after acquiring an additional 8,279 shares during the last quarter. Summit Securities Group LLC acquired a new stake in shares of DocGo in the first quarter worth approximately $34,000. Jane Street Group LLC boosted its stake in shares of DocGo by 18.8% in the first quarter. Jane Street Group LLC now owns 85,442 shares of the company's stock worth $226,000 after acquiring an additional 13,505 shares during the last quarter. Isthmus Partners LLC boosted its stake in shares of DocGo by 2.3% in the first quarter. Isthmus Partners LLC now owns 638,400 shares of the company's stock worth $1,685,000 after acquiring an additional 14,472 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of DocGo by 2,613.3% in the second quarter. CWM LLC now owns 21,978 shares of the company's stock worth $35,000 after acquiring an additional 21,168 shares during the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.